首页 > 最新文献

Endocrine Connections最新文献

英文 中文
Thyroid-stimulating hormone induces insulin resistance in adipocytes via endoplasmic reticulum stress. 促甲状腺激素通过内质网应激诱导脂肪细胞的胰岛素抵抗。
IF 2.6 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-15 Print Date: 2024-08-01 DOI: 10.1530/EC-23-0302
Qing Zhou, Li Yong Zhang, Mei Feng Dai, Zhen Li, Chao Chun Zou, Hui Liu

Graphical abstract:

Abstract: Subclinical hypothyroidism (SCH) is closely related to insulin resistance, and thyroid-stimulating hormone (TSH) level is an independent factor for insulin resistance associated with subclinical hypothyroidism. This study aims to explore the effects of TSH levels on insulin signal transduction in adipocytes and to establish the role of endoplasmic reticulum (ER) stress in this process. In this study, the SCH mouse model was established, and 3T3-L1 adipocytes were treated with TSH or tunicamycin (TM), with or without 4-phenylbutyric acid (4-PBA), an inhibitor of ER stress. Subclinical hypothyroidism mice exhibited impaired glucose tolerance, inactivation of the IRS-1/AKT pathway, and activation of the IRE1/JNK pathway in adipose tissue, which can all be alleviated by 4-PBA. Supplementation with levothyroxine restored the TSH to normal, alongside alleviated ER stress and insulin resistance in SCH mice, which is characterized by improved glucose tolerance, decreased mRNA expression of IRE1, and decreased phosphorylation of JNK in adipose tissue. In 3T3-L1 adipocytes, TSH induces insulin resistance, leading to a decrease in glucose uptake. This effect is mediated by the downregulation of IRS-1 tyrosine phosphorylation, reduced AKT phosphorylation, and inhibited GLUT4 protein expression. Notably, all these effects can be effectively reversed by 4-PBA. Moreover, TSH induced TNF-α and IL-6 production and upregulated the expression of ER stress markers. Similarly, these changes can be recovered by 4-PBA. These findings indicate that TSH has the capability to induce insulin resistance in adipocytes. The mechanism through which TSH disrupts insulin signal transduction appears to involve the ER stress-JNK pathway.

亚临床甲状腺功能减退症(SCH)与胰岛素抵抗密切相关,而促甲状腺激素(TSH)水平是亚临床甲状腺功能减退症相关胰岛素抵抗的一个独立因素。本研究旨在探讨促甲状腺激素水平对脂肪细胞中胰岛素信号转导的影响,并确定内质网(ER)应激在这一过程中的作用。本研究建立了 SCH 小鼠模型,并用 TSH 或妥尼霉素(TM)处理 3T3-L1 脂肪细胞,同时添加或不添加内质网应激抑制剂 4-苯基丁酸(4-PBA)。SCH 小鼠表现出糖耐量受损、IRS-1/AKT 通路失活以及脂肪组织中 IRE1/JNK 通路活化,而 4-PBA 可以缓解这些症状。补充左甲状腺素可使 TSH 恢复正常,同时缓解 SCH 小鼠的 ER 应激和胰岛素抵抗,其特点是糖耐量得到改善,IRE1 的 mRNA 表达减少,脂肪组织中 JNK 的磷酸化降低。在 3T3-L1 脂肪细胞中,TSH 可诱导胰岛素抵抗,导致葡萄糖摄取减少。这种效应是通过下调 IRS-1 酪氨酸磷酸化、减少 AKT 磷酸化和抑制 GLUT4 蛋白表达来实现的。值得注意的是,4-PBA 能有效逆转所有这些效应。此外,TSH 还诱导 TNF-α 和 IL-6 的产生,并上调 ER 应激标记物的表达。同样,4-PBA 也能恢复这些变化。这些发现表明,促肾上腺皮质激素有能力诱导脂肪细胞的胰岛素抵抗。TSH破坏胰岛素信号转导的机制似乎涉及ER应激-JNK途径。
{"title":"Thyroid-stimulating hormone induces insulin resistance in adipocytes via endoplasmic reticulum stress.","authors":"Qing Zhou, Li Yong Zhang, Mei Feng Dai, Zhen Li, Chao Chun Zou, Hui Liu","doi":"10.1530/EC-23-0302","DOIUrl":"10.1530/EC-23-0302","url":null,"abstract":"<p><strong>Graphical abstract: </strong></p><p><strong>Abstract: </strong>Subclinical hypothyroidism (SCH) is closely related to insulin resistance, and thyroid-stimulating hormone (TSH) level is an independent factor for insulin resistance associated with subclinical hypothyroidism. This study aims to explore the effects of TSH levels on insulin signal transduction in adipocytes and to establish the role of endoplasmic reticulum (ER) stress in this process. In this study, the SCH mouse model was established, and 3T3-L1 adipocytes were treated with TSH or tunicamycin (TM), with or without 4-phenylbutyric acid (4-PBA), an inhibitor of ER stress. Subclinical hypothyroidism mice exhibited impaired glucose tolerance, inactivation of the IRS-1/AKT pathway, and activation of the IRE1/JNK pathway in adipose tissue, which can all be alleviated by 4-PBA. Supplementation with levothyroxine restored the TSH to normal, alongside alleviated ER stress and insulin resistance in SCH mice, which is characterized by improved glucose tolerance, decreased mRNA expression of IRE1, and decreased phosphorylation of JNK in adipose tissue. In 3T3-L1 adipocytes, TSH induces insulin resistance, leading to a decrease in glucose uptake. This effect is mediated by the downregulation of IRS-1 tyrosine phosphorylation, reduced AKT phosphorylation, and inhibited GLUT4 protein expression. Notably, all these effects can be effectively reversed by 4-PBA. Moreover, TSH induced TNF-α and IL-6 production and upregulated the expression of ER stress markers. Similarly, these changes can be recovered by 4-PBA. These findings indicate that TSH has the capability to induce insulin resistance in adipocytes. The mechanism through which TSH disrupts insulin signal transduction appears to involve the ER stress-JNK pathway.</p>","PeriodicalId":11634,"journal":{"name":"Endocrine Connections","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nomogram for predicting 5-year metabolic dysfunction-associated steatotic liver disease risk: retrospective cohort study. 预测 5 年代谢功能障碍相关脂肪性肝病风险的提名图:回顾性队列研究。
IF 2.6 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-13 Print Date: 2024-08-01 DOI: 10.1530/EC-24-0186
Lei Gao, Wenxia Cui, Dinghuang Mu, Shaoping Li, Nan Li, Weihong Zhou, Yun Hu

Objective: To create a nomogram-based model to estimate the Chinese population's 5-year risk of metabolic dysfunction-associated steatotic liver disease (MASLD).

Methods: We randomly divided 7582 participants into two groups in a 7:3 ratio: one group was assigned to work with the training set, which consisted of 5307 cases, and the other group was assigned to validate the model using 2275 cases. The least absolute shrinkage and selection operator model was employed to ascertain the variables with the highest correlation among all potential variables. A logistic model was constructed by incorporating these selected variables, which were subsequently visualized using a nomogram. The discriminatory ability, calibration, and clinical utility of the model were assessed using the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA).

Results: During the 5-year follow-up, 1034 (13.64%) total participants were newly diagnosed with MASLD. Using eight variables (gender, body mass index, waist, hemoglobin, alanine aminotransferase, uric acid, triglycerides, and high-density lipoprotein), we built a 5-year MASLD risk prediction model. The nomogram showed an area under the ROC of 0.795 (95% CI: 0.779-0.811) in the training set and 0.785 (95% CI: 0.760-0.810) in the validation set. The calibration curves revealed a 5-year period of agreement between the observed and predicted MASLD risks. DCA curves illustrated the practicality of this nomogram over threshold probability profiles ranging from 5% to 50%.

Conclusion: We created and tested a nomogram to forecast the risk of MASLD prevalence over the next 5 years.

目的建立一个基于提名图的模型,以估算中国人群患代谢功能障碍相关性脂肪性肝病(MASLD)的5年风险:我们按 7:3 的比例将 7582 名参与者随机分为两组:一组负责训练集,包括 5307 个病例;另一组负责使用 2275 个病例验证模型。采用最小绝对收缩和选择算子(LASSO)模型来确定所有潜在变量中相关性最高的变量。通过纳入这些选定的变量,构建了一个逻辑模型,随后使用提名图对这些变量进行了可视化。利用接收器操作特征曲线(ROC)、校准曲线和决策曲线分析(DCA)对模型的判别能力、校准和临床实用性进行了评估:在为期 5 年的随访中,共有 1034 人(13.64%)被新诊断为 MASLD。我们利用 8 个变量(性别、体重指数、腰围、血红蛋白、丙氨酸氨基转移酶、尿酸、甘油三酯和高密度脂蛋白)建立了一个 5 年 MASLD 风险预测模型。提名图显示,训练集的 ROC 下面积为 0.795(95% 置信区间 (CI):0.779-0.811),验证集的 ROC 下面积为 0.785(95% 置信区间 (CI):0.760-0.810)。校准曲线显示,观察到的 MASLD 风险与预测的 MASLD 风险之间存在 5 年的一致性。DCA曲线显示了该提名图在5%到50%的阈值概率范围内的实用性:我们创建并测试了一个预测未来 5 年 MASLD 流行风险的提名图。
{"title":"Nomogram for predicting 5-year metabolic dysfunction-associated steatotic liver disease risk: retrospective cohort study.","authors":"Lei Gao, Wenxia Cui, Dinghuang Mu, Shaoping Li, Nan Li, Weihong Zhou, Yun Hu","doi":"10.1530/EC-24-0186","DOIUrl":"10.1530/EC-24-0186","url":null,"abstract":"<p><strong>Objective: </strong>To create a nomogram-based model to estimate the Chinese population's 5-year risk of metabolic dysfunction-associated steatotic liver disease (MASLD).</p><p><strong>Methods: </strong>We randomly divided 7582 participants into two groups in a 7:3 ratio: one group was assigned to work with the training set, which consisted of 5307 cases, and the other group was assigned to validate the model using 2275 cases. The least absolute shrinkage and selection operator model was employed to ascertain the variables with the highest correlation among all potential variables. A logistic model was constructed by incorporating these selected variables, which were subsequently visualized using a nomogram. The discriminatory ability, calibration, and clinical utility of the model were assessed using the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA).</p><p><strong>Results: </strong>During the 5-year follow-up, 1034 (13.64%) total participants were newly diagnosed with MASLD. Using eight variables (gender, body mass index, waist, hemoglobin, alanine aminotransferase, uric acid, triglycerides, and high-density lipoprotein), we built a 5-year MASLD risk prediction model. The nomogram showed an area under the ROC of 0.795 (95% CI: 0.779-0.811) in the training set and 0.785 (95% CI: 0.760-0.810) in the validation set. The calibration curves revealed a 5-year period of agreement between the observed and predicted MASLD risks. DCA curves illustrated the practicality of this nomogram over threshold probability profiles ranging from 5% to 50%.</p><p><strong>Conclusion: </strong>We created and tested a nomogram to forecast the risk of MASLD prevalence over the next 5 years.</p>","PeriodicalId":11634,"journal":{"name":"Endocrine Connections","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endogenous serum glucocorticoid concentrations, steroidogenic enzyme activity, and 90-day mortality in patients hospitalized with COVID-19: an observational cohort study. COVID-19 住院患者的内源性血清糖皮质激素浓度、类固醇生成酶活性和 90 天死亡率:一项观察性队列研究。
IF 2.6 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-13 Print Date: 2024-08-01 DOI: 10.1530/EC-24-0093
Clara Lundetoft Clausen, Trine Holm Johannsen, Niels Erik Skakkebæk, Hanne Frederiksen, Anders Juul, Thomas Benfield

In the context of severe coronavirus disease 2019 (COVID-19) illness, we examined endogenous glucocorticoid concentrations, steroidogenic enzyme activity, and their correlation with inflammation and patient outcomes. This observational study included 125 hospitalized COVID-19 patients and 101 healthy individuals as a reference group. We utilized LC-MS to assess serum concentrations of 11-deoxycortisol, cortisol, and cortisone, as well as activities of steroidogenic enzymes (11β-hydroxylase and 11β-hydroxysteroid-dehydrogenase type 1). Cox proportional hazards regression analysis and competing risk analysis were employed to analyze associations between glucocorticoid concentrations and outcomes, adjusting for relevant factors. In patients with COVID-19, cortisol concentrations were higher and cortisone concentrations were lower compared to the reference group, while 11-deoxycortisol concentrations were similar. Steroidogenic enzyme activity favored cortisol production. Correlations between glucocorticoid concentrations and inflammatory markers were low. A doubling in concentrations cortisol, was associated with increased 90-day mortality and mechanical ventilation (HR: 2.40 95% CI: (1.03-5.59) , P = 0.042 and HR: 3.83 (1.19-12.31), P = 0.024). A doubling in concentrations of 11-deoxycortisol was also associated to mortality (HR: 1.32 (1.05-1.67), P = 0.018), whereas concentrations of cortisone were associated with mechanical ventilation (HR: 5.09 (1.49-17.40), P = 0.009). In conclusion, serum concentrations of glucocorticoid metabolites were altered in patients hospitalized with severe COVID-19, and steroidogenic enzyme activity resulting in the conversion of cortisone to biologically active cortisol was preserved, thus not favoring critical-illness-related corticosteroid insufficiency at the enzymatic level. Glucocorticoid release did not counterbalance the hyperinflammatory state in patients with severe COVID-19. High serum concentrations of 11-deoxycortisol and cortisol were associated with 90-day mortality, and high serum concentrations of cortisol and cortisone were associated with mechanical ventilation.

在 COVID-19 重症病例中,我们研究了内源性糖皮质激素浓度、类固醇生成酶活性及其与炎症和患者预后的相关性。这项观察性研究包括 125 名住院的 COVID-19 患者和作为参照组的 101 名健康人。我们采用液相色谱-质谱法评估了血清中11-脱氧皮质醇、皮质醇和可的松的浓度以及类固醇生成酶(11β-羟化酶和11β-羟基类固醇-脱氢酶-1型)的活性。在对相关因素进行调整后,采用 Cox 比例危险回归分析和竞争风险分析来分析糖皮质激素浓度与结果之间的关系。与参照组相比,COVID-19 患者的皮质醇浓度较高,可的松浓度较低,而 11-脱氧皮质醇浓度相似。类固醇生成酶的活性有利于皮质醇的生成。糖皮质激素浓度与炎症指标之间的相关性较低。皮质醇浓度增加一倍与 90 天死亡率和机械通气增加有关(HR2.40 95% CI (1.03-5.59),P=0.042 和 HR 3.83 (1.19-12.31),P=0.024)。11-脱氧皮质醇浓度增加一倍也与死亡率有关(HR 1.32 (1.05-1.67),p=0.018),而可的松浓度与机械通气有关(HR 5.09 (1.49-17.40),p=0.009))。总之,重症 COVID-19 住院患者血清中糖皮质激素代谢物的浓度发生了变化,而导致可的松转化为具有生物活性的皮质醇的类固醇生成酶活性得到了保留,因此在酶水平上并不倾向于危重病相关皮质类固醇缺乏症。糖皮质激素的释放并不能抵消严重 COVID-19 患者的高炎症状态。高血清浓度的11-脱氧皮质醇和皮质醇与90天死亡率有关,高血清浓度的皮质醇和可的松与机械通气有关。
{"title":"Endogenous serum glucocorticoid concentrations, steroidogenic enzyme activity, and 90-day mortality in patients hospitalized with COVID-19: an observational cohort study.","authors":"Clara Lundetoft Clausen, Trine Holm Johannsen, Niels Erik Skakkebæk, Hanne Frederiksen, Anders Juul, Thomas Benfield","doi":"10.1530/EC-24-0093","DOIUrl":"10.1530/EC-24-0093","url":null,"abstract":"<p><p>In the context of severe coronavirus disease 2019 (COVID-19) illness, we examined endogenous glucocorticoid concentrations, steroidogenic enzyme activity, and their correlation with inflammation and patient outcomes. This observational study included 125 hospitalized COVID-19 patients and 101 healthy individuals as a reference group. We utilized LC-MS to assess serum concentrations of 11-deoxycortisol, cortisol, and cortisone, as well as activities of steroidogenic enzymes (11β-hydroxylase and 11β-hydroxysteroid-dehydrogenase type 1). Cox proportional hazards regression analysis and competing risk analysis were employed to analyze associations between glucocorticoid concentrations and outcomes, adjusting for relevant factors. In patients with COVID-19, cortisol concentrations were higher and cortisone concentrations were lower compared to the reference group, while 11-deoxycortisol concentrations were similar. Steroidogenic enzyme activity favored cortisol production. Correlations between glucocorticoid concentrations and inflammatory markers were low. A doubling in concentrations cortisol, was associated with increased 90-day mortality and mechanical ventilation (HR: 2.40 95% CI: (1.03-5.59) , P = 0.042 and HR: 3.83 (1.19-12.31), P = 0.024). A doubling in concentrations of 11-deoxycortisol was also associated to mortality (HR: 1.32 (1.05-1.67), P = 0.018), whereas concentrations of cortisone were associated with mechanical ventilation (HR: 5.09 (1.49-17.40), P = 0.009). In conclusion, serum concentrations of glucocorticoid metabolites were altered in patients hospitalized with severe COVID-19, and steroidogenic enzyme activity resulting in the conversion of cortisone to biologically active cortisol was preserved, thus not favoring critical-illness-related corticosteroid insufficiency at the enzymatic level. Glucocorticoid release did not counterbalance the hyperinflammatory state in patients with severe COVID-19. High serum concentrations of 11-deoxycortisol and cortisol were associated with 90-day mortality, and high serum concentrations of cortisol and cortisone were associated with mechanical ventilation.</p>","PeriodicalId":11634,"journal":{"name":"Endocrine Connections","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prader-Willi syndrome: guidance for children and transition into adulthood. 普拉德-威利综合症:儿童指导和成年过渡。
IF 2.6 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-10 Print Date: 2024-08-01 DOI: 10.1530/EC-24-0091
M Guftar Shaikh, Timothy G Barrett, Nicola Bridges, Robin Chung, Evelien F Gevers, Anthony P Goldstone, Anthony Holland, Shankar Kanumakala, Ruth Krone, Andreas Kyriakou, E Anne Livesey, Angela K Lucas-Herald, Christina Meade, Susan Passmore, Edna Roche, Chris Smith, Sarita Soni

Prader-Willi syndrome (PWS) is a rare orphan disease and complex genetic neurodevelopmental disorder, with a birth incidence of approximately 1 in 10,000-30,000. Management of people with PWS requires a multi-disciplinary approach, ideally through a multi-disciplinary team (MDT) clinic with community support. Hypotonia, poor feeding and faltering growth are characteristic features in the neonatal period, followed by hyperphagia and risk of rapid weight gain later in childhood. Children and adolescents (CA) with PWS usually display developmental delay and mild learning disability and can develop endocrinopathies, scoliosis, respiratory difficulties (both central and obstructive sleep apnoea), challenging behaviours, skin picking, and mental health issues, especially into adulthood. This consensus statement is intended to be a reference document for clinicians managing children and adolescents (up to 18 years of age) with PWS. It considers the bio-psycho-social domains of diagnosis, clinical assessment, and management in the paediatric setting as well as during and after transition to adult services. The guidance has been developed from information gathered from peer-reviewed scientific reports and from the expertise of a range of experienced clinicians in the United Kingdom and Ireland involved in the care of patients with PWS.

普拉德-威利综合征(PWS)是一种罕见的孤儿病和复杂的遗传性神经发育障碍,出生率约为万分之一到三万分之一。对普氏综合症患者的管理需要多学科方法,最好是通过多学科团队(MDT)诊所,并在社区的支持下进行。肌张力低下、喂养不良和发育迟缓是新生儿期的特征,随后会出现多食和儿童期体重快速增长的风险。患有PWS的儿童和青少年(CA)通常表现出发育迟缓和轻度学习障碍,并可能发展成内分泌疾病、脊柱侧弯、呼吸困难(中枢性和阻塞性睡眠呼吸暂停)、挑战性行为、皮肤搔痒和心理健康问题,尤其是在成年后。本共识声明旨在为临床医生管理患有脊髓灰质炎的儿童和青少年(18 岁以下)提供一份参考文件。它考虑了儿科环境中的诊断、临床评估和管理,以及过渡到成人服务期间和之后的生物-心理-社会领域。该指南是从同行评议的科学报告中收集的信息,以及英国和爱尔兰参与护理 PWS 患者的一系列经验丰富的临床医生的专业知识编写而成的。
{"title":"Prader-Willi syndrome: guidance for children and transition into adulthood.","authors":"M Guftar Shaikh, Timothy G Barrett, Nicola Bridges, Robin Chung, Evelien F Gevers, Anthony P Goldstone, Anthony Holland, Shankar Kanumakala, Ruth Krone, Andreas Kyriakou, E Anne Livesey, Angela K Lucas-Herald, Christina Meade, Susan Passmore, Edna Roche, Chris Smith, Sarita Soni","doi":"10.1530/EC-24-0091","DOIUrl":"10.1530/EC-24-0091","url":null,"abstract":"<p><p>Prader-Willi syndrome (PWS) is a rare orphan disease and complex genetic neurodevelopmental disorder, with a birth incidence of approximately 1 in 10,000-30,000. Management of people with PWS requires a multi-disciplinary approach, ideally through a multi-disciplinary team (MDT) clinic with community support. Hypotonia, poor feeding and faltering growth are characteristic features in the neonatal period, followed by hyperphagia and risk of rapid weight gain later in childhood. Children and adolescents (CA) with PWS usually display developmental delay and mild learning disability and can develop endocrinopathies, scoliosis, respiratory difficulties (both central and obstructive sleep apnoea), challenging behaviours, skin picking, and mental health issues, especially into adulthood. This consensus statement is intended to be a reference document for clinicians managing children and adolescents (up to 18 years of age) with PWS. It considers the bio-psycho-social domains of diagnosis, clinical assessment, and management in the paediatric setting as well as during and after transition to adult services. The guidance has been developed from information gathered from peer-reviewed scientific reports and from the expertise of a range of experienced clinicians in the United Kingdom and Ireland involved in the care of patients with PWS.</p>","PeriodicalId":11634,"journal":{"name":"Endocrine Connections","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141260324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digital therapeutics as an emerging new therapy for diabetes mellitus: potentials and concerns. 数字疗法作为一种新兴的糖尿病新疗法:潜力与担忧。
IF 2.6 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-01 DOI: 10.1530/EC-24-0219
Shanhong Li, Jincheng Tao, Jie Tang, Yanting Chu, Huiqun Wu

The global burden of controlling and managing diabetes mellitus (DM) is a significant challenge. Despite the advancements in conventional DM therapy, there remain hurdles to overcome, such as enhancing medication adherence and improving patient prognosis. Digital therapeutics (DTx), an innovative digital application, has been proposed to augment the traditional disease management workflow, particularly in managing chronic diseases like DM. Several studies have explored DTx, yielding promising results. However, certain concerns about this innovation persist. In this review, we aim to encapsulate the potential of DTx and its applications in DM management, thereby providing a comprehensive overview of this technique for public health policymakers.

控制和管理糖尿病(DM)给全球带来的负担是一项重大挑战。尽管传统的糖尿病治疗方法取得了进步,但仍有一些障碍需要克服,如提高服药依从性和改善患者预后。数字疗法(DTx)是一种创新的数字应用,已被提出来增强传统的疾病管理工作流程,尤其是在管理糖尿病等慢性病方面。已有多项研究对 DTx 进行了探索,并取得了可喜的成果。然而,对这一创新的某些担忧依然存在。在这篇综述中,我们旨在概括 DTx 的潜力及其在 DM 管理中的应用,从而为公共卫生决策者提供有关这一技术的全面概述。
{"title":"Digital therapeutics as an emerging new therapy for diabetes mellitus: potentials and concerns.","authors":"Shanhong Li, Jincheng Tao, Jie Tang, Yanting Chu, Huiqun Wu","doi":"10.1530/EC-24-0219","DOIUrl":"10.1530/EC-24-0219","url":null,"abstract":"<p><p>The global burden of controlling and managing diabetes mellitus (DM) is a significant challenge. Despite the advancements in conventional DM therapy, there remain hurdles to overcome, such as enhancing medication adherence and improving patient prognosis. Digital therapeutics (DTx), an innovative digital application, has been proposed to augment the traditional disease management workflow, particularly in managing chronic diseases like DM. Several studies have explored DTx, yielding promising results. However, certain concerns about this innovation persist. In this review, we aim to encapsulate the potential of DTx and its applications in DM management, thereby providing a comprehensive overview of this technique for public health policymakers.</p>","PeriodicalId":11634,"journal":{"name":"Endocrine Connections","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11378137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two weeks of acarbose treatment shows no effect on gut microbiome composition in patients with type 2 diabetes: a randomised, placebo-controlled, double-blind, crossover study. 为期两周的阿卡波糖治疗对 2 型糖尿病患者的肠道微生物组组成没有影响:一项随机、安慰剂对照、双盲、交叉研究。
IF 2.6 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-06-28 Print Date: 2024-07-01 DOI: 10.1530/EC-24-0052
Niels B Dalsgaard, Lærke S Gasbjerg, Laura S Hansen, Dennis S Nielsen, Torben S Rasmussen, Filip K Knop

Aim: The alpha-glucosidase inhibitor acarbose is approved for the treatment of type 2 diabetes (T2D). It acts in the lumen of the gut by reducing intestinal hydrolysis and absorption of ingested carbohydrates. This reduces postprandial blood glucose concentration and increases the content of carbohydrates in the distal parts of the intestine potentially influencing gut microbiome (GM) composition and possibly impacting the gut microbiome (GM) dysbiosis associated with T2D. Here, we investigated the effect of acarbose on GM composition in patients with T2D.

Methods: Faecal samples were collected in a previously conducted randomised, placebo-controlled, double-blind, crossover study in which 15 individuals with metformin-treated T2D (age 57-85 years, HbA1c 40-74 mmol/mol, BMI 23.6-34.6 kg/m2) were subjected to two 14-day treatment periods with acarbose and placebo, respectively, separated by a 6-week wash-out period. Faecal samples were collected before and by the end of each treatment period. The GM profiles were evaluated by 16S rRNA gene amplicon sequencing.

Results: The GM profiles after the treatment periods with acarbose or placebo remained unaffected (P > 0.7) when compared with the GM profiles before treatment. This applied to the analysis of within-sample diversity (α-diversity) and between-sample bacterial composition diversity (β-diversity). Additionally, no dominant bacterial species differentiated the treatment groups, and only minor increases in the relative abundances of Klebsiella spp. and Escherichia coli (P < 0.05) were observed after acarbose treatment.

Conclusion: In patients with metformin-treated T2D, 14 days of treatment with acarbose showed only minor effects on GM as seen in increased relative abundances of Klebsiella spp. and Escherichia coli.

目的:α-葡萄糖苷酶抑制剂阿卡波糖已被批准用于治疗 2 型糖尿病(T2D)。它在肠道腔内发挥作用,减少肠道对摄入碳水化合物的水解和吸收。这降低了餐后血糖浓度,增加了肠道远端碳水化合物的含量,有可能影响肠道微生物组(GM)的组成,从而可能影响与 T2D 相关的肠道微生物组(GM)菌群失调。在此,我们研究了阿卡波糖对 T2D 患者肠道微生物组组成的影响:在之前进行的一项随机、安慰剂对照、双盲、交叉研究中收集的粪便样本中,15 名接受二甲双胍治疗的 T2D 患者(年龄 57-85 岁,HbA1c 40-74 mmol/mol,BMI 23.6 - 34.6 kg/m2)分别接受了为期 14 天的阿卡波糖和安慰剂治疗,中间有六周的冲洗期。在每个疗程开始前和结束时收集粪便样本。采用 16S rRNA 基因扩增片段测序法对转基因特征进行评估:结果:与治疗前相比,阿卡波糖或安慰剂治疗期结束后的基因组概况未受影响(P > 0.7)。这既适用于样本内多样性(α-多样性)分析,也适用于样本间细菌组成多样性(β-多样性)分析。此外,阿卡波糖治疗后,治疗组之间没有优势细菌物种的差异,仅观察到克雷伯氏菌属和大肠埃希氏菌的相对丰度略有增加(P < 0.05):结论:在二甲双胍治疗的 T2D 患者中,阿卡波糖治疗 14 天仅对转基因产生生理上不重要的影响。
{"title":"Two weeks of acarbose treatment shows no effect on gut microbiome composition in patients with type 2 diabetes: a randomised, placebo-controlled, double-blind, crossover study.","authors":"Niels B Dalsgaard, Lærke S Gasbjerg, Laura S Hansen, Dennis S Nielsen, Torben S Rasmussen, Filip K Knop","doi":"10.1530/EC-24-0052","DOIUrl":"10.1530/EC-24-0052","url":null,"abstract":"<p><strong>Aim: </strong>The alpha-glucosidase inhibitor acarbose is approved for the treatment of type 2 diabetes (T2D). It acts in the lumen of the gut by reducing intestinal hydrolysis and absorption of ingested carbohydrates. This reduces postprandial blood glucose concentration and increases the content of carbohydrates in the distal parts of the intestine potentially influencing gut microbiome (GM) composition and possibly impacting the gut microbiome (GM) dysbiosis associated with T2D. Here, we investigated the effect of acarbose on GM composition in patients with T2D.</p><p><strong>Methods: </strong>Faecal samples were collected in a previously conducted randomised, placebo-controlled, double-blind, crossover study in which 15 individuals with metformin-treated T2D (age 57-85 years, HbA1c 40-74 mmol/mol, BMI 23.6-34.6 kg/m2) were subjected to two 14-day treatment periods with acarbose and placebo, respectively, separated by a 6-week wash-out period. Faecal samples were collected before and by the end of each treatment period. The GM profiles were evaluated by 16S rRNA gene amplicon sequencing.</p><p><strong>Results: </strong>The GM profiles after the treatment periods with acarbose or placebo remained unaffected (P > 0.7) when compared with the GM profiles before treatment. This applied to the analysis of within-sample diversity (α-diversity) and between-sample bacterial composition diversity (β-diversity). Additionally, no dominant bacterial species differentiated the treatment groups, and only minor increases in the relative abundances of Klebsiella spp. and Escherichia coli (P < 0.05) were observed after acarbose treatment.</p><p><strong>Conclusion: </strong>In patients with metformin-treated T2D, 14 days of treatment with acarbose showed only minor effects on GM as seen in increased relative abundances of Klebsiella spp. and Escherichia coli.</p>","PeriodicalId":11634,"journal":{"name":"Endocrine Connections","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141260327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of the quality, content, and reliability of YouTube® videos on diabetes mellitus and polycystic ovary syndrome: a systematic review with cross-sectional analysis comparing peer-reviewed videos. YouTube®糖尿病和多囊卵巢综合症视频的质量、内容和可靠性评估:比较同行评审视频的横断面分析系统综述。
IF 2.6 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-06-28 Print Date: 2024-07-01 DOI: 10.1530/EC-24-0059
Shams Ali Baig, Kashish Malhotra, Anagh Josh Banerjee, Mukunth Kowsik, Khushi Kumar, Fazna Rahman, Syeda Sabbah Batul, Mohammed Faraaz Saiyed, Vardhan Venkatesh, Pranav Viswanath Iyer, Punith Kempegowda

YouTube® is one of the leading platforms for health information. However, the lack of regulation of content and quality raises concerns about accuracy and reliability. CoMICs (Concise Medical Information Cines) are evidence-based short videos created by medical students and junior doctors and reviewed by experts to ensure clinical accuracy. We performed a systematic review to understand the impact of videos on knowledge and awareness about diabetes and PCOS. We then evaluated the quality of YouTube® videos about diabetes and PCOS using various validated quality assessment tools and compared these with CoMICs videos on the same topics. Quality assessment tools like DISCERN, JAMA benchmark criteria, and global quality scale (GQS) score were employed. Some of the authors of this study also co-authored the creation of some of the CoMICs evaluated. Our study revealed that while videos effectively improve understanding of diabetes and PCOS, there are notable differences in quality and reliability of the videos on YouTube®. For diabetes, CoMICs videos had higher DISCERN scores (CoMICs vs YouTube®: 2.4 vs 1.6), superior reliability (P < 0.01), and treatment quality (P < 0.01) and met JAMA criteria for authorship (100% vs 30.6%) and currency (100% vs 53.1%). For PCOS, CoMICs had higher DISCERN scores (2.9 vs 1.9), reliability (P < 0.01), and treatment quality (P < 0.01); met JAMA criteria for authorship (100% vs 34.0%) and currency (100% vs 54.0%); and had higher GQS scores (4.0 vs 3.0). In conclusion, CoMICs outperformed other similar sources on YouTube® in providing reliable evidence-based medical information which may be used for patient education.

YouTube® 是健康信息的主要平台之一。然而,由于缺乏对内容和质量的监管,人们对其准确性和可靠性产生了担忧。CoMIC(简明医学信息视频)是由医科学生和初级医生制作的基于证据的短视频,并由专家进行审核,以确保临床准确性。我们进行了一项系统性回顾,以了解视频对糖尿病和多囊卵巢综合症知识和认知的影响。然后,我们使用各种经过验证的质量评估工具对 YouTube® 上有关糖尿病和多囊卵巢综合症的视频进行了质量评估,并将其与 CoMICs 上相同主题的视频进行了比较。我们使用了 DISCERN、JAMA 基准标准和全球质量评分 (GQS) 等质量评估工具。本研究的一些作者还与他人共同创作了一些被评估的 CoMICs。我们的研究表明,虽然视频能有效增进人们对糖尿病和多囊卵巢综合症的了解,但 YouTube® 上的视频在质量和可靠性方面存在明显差异。在糖尿病方面,CoMICs 视频的 DISCERN 分数更高(CoMICs vs YouTube®:2.4 vs 1.6),可靠性更高(p
{"title":"Assessment of the quality, content, and reliability of YouTube® videos on diabetes mellitus and polycystic ovary syndrome: a systematic review with cross-sectional analysis comparing peer-reviewed videos.","authors":"Shams Ali Baig, Kashish Malhotra, Anagh Josh Banerjee, Mukunth Kowsik, Khushi Kumar, Fazna Rahman, Syeda Sabbah Batul, Mohammed Faraaz Saiyed, Vardhan Venkatesh, Pranav Viswanath Iyer, Punith Kempegowda","doi":"10.1530/EC-24-0059","DOIUrl":"10.1530/EC-24-0059","url":null,"abstract":"<p><p>YouTube® is one of the leading platforms for health information. However, the lack of regulation of content and quality raises concerns about accuracy and reliability. CoMICs (Concise Medical Information Cines) are evidence-based short videos created by medical students and junior doctors and reviewed by experts to ensure clinical accuracy. We performed a systematic review to understand the impact of videos on knowledge and awareness about diabetes and PCOS. We then evaluated the quality of YouTube® videos about diabetes and PCOS using various validated quality assessment tools and compared these with CoMICs videos on the same topics. Quality assessment tools like DISCERN, JAMA benchmark criteria, and global quality scale (GQS) score were employed. Some of the authors of this study also co-authored the creation of some of the CoMICs evaluated. Our study revealed that while videos effectively improve understanding of diabetes and PCOS, there are notable differences in quality and reliability of the videos on YouTube®. For diabetes, CoMICs videos had higher DISCERN scores (CoMICs vs YouTube®: 2.4 vs 1.6), superior reliability (P < 0.01), and treatment quality (P < 0.01) and met JAMA criteria for authorship (100% vs 30.6%) and currency (100% vs 53.1%). For PCOS, CoMICs had higher DISCERN scores (2.9 vs 1.9), reliability (P < 0.01), and treatment quality (P < 0.01); met JAMA criteria for authorship (100% vs 34.0%) and currency (100% vs 54.0%); and had higher GQS scores (4.0 vs 3.0). In conclusion, CoMICs outperformed other similar sources on YouTube® in providing reliable evidence-based medical information which may be used for patient education.</p>","PeriodicalId":11634,"journal":{"name":"Endocrine Connections","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cold exposure increases circulating fibroblast growth factor 21 in the evening in males and females. 傍晚时分,男性和女性体内的循环成纤维细胞生长因子 21 会因寒冷而增加。
IF 2.6 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-06-18 Print Date: 2024-07-01 DOI: 10.1530/EC-24-0074
Carlijn A Hoekx, Borja Martinez-Tellez, Maaike E Straat, Magdalena M A Verkleij, Mirjam Kemmeren, Sander Kooijman, Martin Uhrbom, Saskia C A de Jager, Patrick C N Rensen, Mariëtte R Boon

Objectives: Cold exposure is linked to cardiometabolic benefits. Cold activates brown adipose tissue (BAT), increases energy expenditure, and induces secretion of the hormones fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15). The cold-induced increase in energy expenditure exhibits a diurnal rhythm in men. Therefore, we aimed to investigate the effect of cold exposure on serum FGF21 and GDF15 levels in humans and whether cold-induced changes in FGF21 and GDF15 levels differ between morning and evening in males and females.

Method: In this randomized cross-over study, serum FGF21 and GDF15 levels were measured in healthy lean males (n = 12) and females (n = 12) before, during, and after 90 min of stable cold exposure in the morning (07:45 h) and evening (19:45 h) with a 1-day washout period in between.

Results: Cold exposure increased FGF21 levels in the evening compared to the morning both in males (+61% vs -13%; P < 0.001) and in females (+58% vs +8%; P < 0.001). In contrast, cold exposure did not significantly modify serum GDF15 levels, and no diurnal variation was found. Changes in FGF21 and GDF15 levels did not correlate with changes in cold-induced energy expenditure in the morning and evening.

Conclusion: Cold exposure increased serum FGF21 levels in the evening, but not in the morning, in both males and females. GDF15 levels were not affected by cold exposure. Thus, this study suggests that the timing of cold exposure may influence cold-induced changes in FGF21 levels but not GDF15 levels and seems to be independent of changes in energy expenditure.

目的:寒冷与心脏代谢的益处有关。寒冷可激活棕色脂肪组织(BAT),增加能量消耗,并诱导成纤维细胞生长因子 21(FGF21)和生长分化因子 15(GDF15)等激素的分泌。寒冷引起的能量消耗增加在男性中表现出昼夜节律。因此,我们旨在研究寒冷暴露对人体血清 FGF21 和 GDF15 水平的影响,以及寒冷诱导的 FGF21 和 GDF15 水平变化在男性和女性的早晚是否有所不同:在这项随机交叉研究中,分别在早晨(7:45am)和傍晚(7:45pm)进行90分钟稳定的冷暴露之前、期间和之后,测量健康瘦男性(n=12)和女性(n=12)的血清FGF21和GDF15水平,中间有一天的冲洗期:结果:与早晨相比,男性在傍晚暴露于寒冷会增加 FGF21 水平(+61% 对 -13%;PC 结论:暴露于寒冷会增加血清中的 FGF21 水平:寒冷暴露会增加男性和女性晚上的血清 FGF21 水平,而不是早上的水平。GDF15 的水平不受寒冷影响。因此,这项研究表明,寒冷暴露的时间可能会影响寒冷诱导的 FGF21 水平变化,但不会影响 GDF15 水平,而且似乎与能量消耗的变化无关。
{"title":"Cold exposure increases circulating fibroblast growth factor 21 in the evening in males and females.","authors":"Carlijn A Hoekx, Borja Martinez-Tellez, Maaike E Straat, Magdalena M A Verkleij, Mirjam Kemmeren, Sander Kooijman, Martin Uhrbom, Saskia C A de Jager, Patrick C N Rensen, Mariëtte R Boon","doi":"10.1530/EC-24-0074","DOIUrl":"10.1530/EC-24-0074","url":null,"abstract":"<p><strong>Objectives: </strong>Cold exposure is linked to cardiometabolic benefits. Cold activates brown adipose tissue (BAT), increases energy expenditure, and induces secretion of the hormones fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15). The cold-induced increase in energy expenditure exhibits a diurnal rhythm in men. Therefore, we aimed to investigate the effect of cold exposure on serum FGF21 and GDF15 levels in humans and whether cold-induced changes in FGF21 and GDF15 levels differ between morning and evening in males and females.</p><p><strong>Method: </strong>In this randomized cross-over study, serum FGF21 and GDF15 levels were measured in healthy lean males (n = 12) and females (n = 12) before, during, and after 90 min of stable cold exposure in the morning (07:45 h) and evening (19:45 h) with a 1-day washout period in between.</p><p><strong>Results: </strong>Cold exposure increased FGF21 levels in the evening compared to the morning both in males (+61% vs -13%; P < 0.001) and in females (+58% vs +8%; P < 0.001). In contrast, cold exposure did not significantly modify serum GDF15 levels, and no diurnal variation was found. Changes in FGF21 and GDF15 levels did not correlate with changes in cold-induced energy expenditure in the morning and evening.</p><p><strong>Conclusion: </strong>Cold exposure increased serum FGF21 levels in the evening, but not in the morning, in both males and females. GDF15 levels were not affected by cold exposure. Thus, this study suggests that the timing of cold exposure may influence cold-induced changes in FGF21 levels but not GDF15 levels and seems to be independent of changes in energy expenditure.</p>","PeriodicalId":11634,"journal":{"name":"Endocrine Connections","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic accuracy of Afirma gene expression classifier, Afirma gene sequencing classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis. Afirma 基因表达分类器、Afirma 基因测序分类器、ThyroSeq v2 和 ThyroSeq v3 对不确定甲状腺结节(Bethesda III 和 IV)的诊断准确性:一项荟萃分析。
IF 2.6 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-06-13 Print Date: 2024-07-01 DOI: 10.1530/EC-24-0170
Irfan Vardarli, Susanne Tan, Rainer Görges, Bernhard K Krämer, Ken Herrmann, Christoph Brochhausen

Objective: The management of thyroid nodules with indeterminate cytology (ITN) is still a challenge. To evaluate the performance of commercial molecular tests for ITN, we performed this comprehensive meta-analysis.

Methods: We performed an electronic search using PubMed/Medline, Embase, and the Cochrane Library. Studies assessing the diagnostic accuracy of Afirma gene expression classifier (GEC), Afirma gene sequencing classifier (GSC), ThyroSeq v2 (TSv2), or ThyroSeq v3 (TSv3) in patients with ITN (only Bethesda category III or IV) were selected; Statistical analyses were performed by using Stata.

Results: Seventy-one samples (GEC, n = 38; GSC, n = 16; TSv2, n = 9; TSv3, n = 8) in 53 studies, involving 6490 fine needle aspirations (FNAs) with ITN cytology with molecular diagnostics (GEC, GSC, TSv2, or TSv3), were included in the study. The meta-analysis showed the following pooled estimates: sensitivity 0.95 (95% CI: 0.94-0.97), specificity 0.35 (0.28-0.43), positive likelihood ratio (LR+) 1.5 (1.3-1.6), and negative likelihood ratio (LR-) 0.13 (0.09-0.19), with the best performance for TSv3 (area under the ROC curve 0.95 (0.93-0.96), followed by TSv2 (0.90 (0.87-0.92)), GSC (0.86 (0.82-0.88)), and GEC (0.82 (0.78-0.85)); the best rule-out property was observed for GSC (LR-, 0.07 (0.02-0.19)), followed by TSv3 (0.11 (0.05-0.24)) and GEC (0.16 (0.10-0.28), and the best rule-in was observed for TSv2 (LR+, 2,9 (1.4-4.6)), followed by GSC (1.9 (1.6-2.4)). A meta-regression analysis revealed that study design, Bethesda category, and type of molecular test were independent factors.

Conclusion: We showed that in patients with ITN, TSv3 has the best molecular diagnostic performance, followed by TSv2, GSC, and GEC. As regards rule-out malignancy, GSC, and rule-in, TSV2 is superior to other tests.

目的:对细胞学(ITN)不确定的甲状腺结节的处理仍是一项挑战。为了评估商用分子检验在 ITN 方面的性能,我们进行了这项综合荟萃分析:我们使用 PubMed/Medline、Embase 和 Cochrane 图书馆进行了电子检索。筛选出评估 Afirma 基因表达分类器 (GEC)、Afirma 基因测序分类器 (GSC)、ThyroSeq v2 (TSv2) 或 ThyroSeq v3 (TSv3) 对 ITN 患者(仅 Bethesda III 或 IV 类)诊断准确性的研究;使用 Stata 进行统计分析:53项研究中的71个样本(GEC,n=38;GSC,n=16;TSv2,n=9;TSv3,n=8)被纳入研究,涉及6490例ITN细胞学分子诊断(GEC、GSC、TSv2或TSv3)的细针穿刺(FNA)。Meta 分析显示了以下汇总估计值:灵敏度 0.95(95% CI,0.94-0.97),特异性 0.35(0.28-0.43),阳性似然比 (LR+) 1.5(1.3-1.6),阴性似然比 (LR-) 0.13(0.09-0.19),其中 TSv3 的表现最佳(ROC 曲线下面积 0.95(0.93-0.96),其次是 TSv2。96),其次是 TSv2(0.90(0.87-0.92))、GSC(0.86(0.82-0.88))和 GEC(0.82(0.78-0.85));排除性能最好的是 GSC(LR-,0.07(0.02-0.19)),其次是 TSv3(0.11(0.05-0.24))和 GEC(0.16(0.10-0.28));TSv2 的规则入属性最好(LR+,2.9(1.4-4.6)),其次是 GSC(1.9(1.6-2.4))。元回归分析显示,研究设计、贝塞斯达类别和分子检测类型是独立因素:我们发现,在 ITN 患者中,TSv3 的分子诊断效果最好,其次是 TSv2、GSC 和 GEC。在排除恶性肿瘤方面,GSC和TSV2优于其他检验。
{"title":"Diagnostic accuracy of Afirma gene expression classifier, Afirma gene sequencing classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis.","authors":"Irfan Vardarli, Susanne Tan, Rainer Görges, Bernhard K Krämer, Ken Herrmann, Christoph Brochhausen","doi":"10.1530/EC-24-0170","DOIUrl":"10.1530/EC-24-0170","url":null,"abstract":"<p><strong>Objective: </strong>The management of thyroid nodules with indeterminate cytology (ITN) is still a challenge. To evaluate the performance of commercial molecular tests for ITN, we performed this comprehensive meta-analysis.</p><p><strong>Methods: </strong>We performed an electronic search using PubMed/Medline, Embase, and the Cochrane Library. Studies assessing the diagnostic accuracy of Afirma gene expression classifier (GEC), Afirma gene sequencing classifier (GSC), ThyroSeq v2 (TSv2), or ThyroSeq v3 (TSv3) in patients with ITN (only Bethesda category III or IV) were selected; Statistical analyses were performed by using Stata.</p><p><strong>Results: </strong>Seventy-one samples (GEC, n = 38; GSC, n = 16; TSv2, n = 9; TSv3, n = 8) in 53 studies, involving 6490 fine needle aspirations (FNAs) with ITN cytology with molecular diagnostics (GEC, GSC, TSv2, or TSv3), were included in the study. The meta-analysis showed the following pooled estimates: sensitivity 0.95 (95% CI: 0.94-0.97), specificity 0.35 (0.28-0.43), positive likelihood ratio (LR+) 1.5 (1.3-1.6), and negative likelihood ratio (LR-) 0.13 (0.09-0.19), with the best performance for TSv3 (area under the ROC curve 0.95 (0.93-0.96), followed by TSv2 (0.90 (0.87-0.92)), GSC (0.86 (0.82-0.88)), and GEC (0.82 (0.78-0.85)); the best rule-out property was observed for GSC (LR-, 0.07 (0.02-0.19)), followed by TSv3 (0.11 (0.05-0.24)) and GEC (0.16 (0.10-0.28), and the best rule-in was observed for TSv2 (LR+, 2,9 (1.4-4.6)), followed by GSC (1.9 (1.6-2.4)). A meta-regression analysis revealed that study design, Bethesda category, and type of molecular test were independent factors.</p><p><strong>Conclusion: </strong>We showed that in patients with ITN, TSv3 has the best molecular diagnostic performance, followed by TSv2, GSC, and GEC. As regards rule-out malignancy, GSC, and rule-in, TSV2 is superior to other tests.</p>","PeriodicalId":11634,"journal":{"name":"Endocrine Connections","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141070724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SLC7A11 promotes EMT and metastasis in invasive pituitary neuroendocrine tumors by activating the PI3K/AKT signaling pathway. SLC7A11通过激活PI3K/AKT信号通路促进侵袭性垂体神经内分泌肿瘤的EMT和转移。
IF 2.6 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-06-03 Print Date: 2024-07-01 DOI: 10.1530/EC-24-0097
Shikai Gui, Wanli Yu, Jiabao Xie, Lunshan Peng, Yuanyuan Xiong, Zhen Song, Haitao Luo, Juexian Xiao, Shengtao Yuan, Zujue Cheng

Invasive pituitary neuroendocrine tumors (PitNETs) are the most prevalent types of intracranial and neuroendocrine tumors. Their aggressive growth and difficulty in complete resection result in a high recurrence rate. Cystine transporter solute carrier family 7 member 11 (SLC7A11) is overexpressed in various cancers, which contributes to tumor growth, progression, and metastasis by promoting cystine uptake and glutathione biosynthesis. We identified SLC7A11 as an invasive biomarker based on three Gene Expression Omnibus cohorts. This study aimed to investigate the role of SLC7A11 in invasive PitNETs. Cell proliferation was assessed using CCK-8 and colony formation assays, while cell apoptosis was estimated with flow cytometry. Wound healing assays and transwell assays were utilized to evaluate migration and invasion ability. Our findings demonstrated that SLC7A11 was markedly upregulated in invasive PitNETs, and was associated with the invasiveness of PitNETs. Knockdown of SLC7A11 could largely suppress tumor cell proliferation, migration, and invasion, while inducing apoptosis. Furthermore, SLC7A11 depletion was implicated in regulating epithelial-mesenchymal transition and inactivating the PI3K/AKT signaling pathway. These insights suggest SLC7A11 as a potential therapeutic target for invasive PitNETs.

侵袭性垂体神经内分泌肿瘤(PitNETs)是颅内和神经内分泌肿瘤中最常见的类型。由于其生长具有侵袭性,难以完全切除,因此复发率很高。胱氨酸转运体溶质运载家族 7 成员 11(SLC7A11)在多种癌症中过度表达,通过促进胱氨酸摄取和谷胱甘肽的生物合成,促使肿瘤生长、恶化和转移。我们基于三个 GEO 队列发现 SLC7A11 是一种侵袭性生物标记物。本研究旨在探讨SLC7A11在侵袭性PitNET中的作用。细胞增殖采用CCK-8和集落形成试验进行评估,细胞凋亡采用流式细胞术进行估计。伤口愈合试验和透孔试验用于评估迁移和侵袭能力。我们的研究结果表明,SLC7A11在侵袭性PitNET中明显上调,并且与PitNET的侵袭性有关。敲除SLC7A11能在很大程度上抑制肿瘤细胞的增殖、迁移和侵袭,同时诱导细胞凋亡。此外,SLC7A11的耗竭还与调节EMT和使PI3K/AKT信号通路失活有关。这些发现表明,SLC7A11是侵袭性PitNET的潜在治疗靶点。
{"title":"SLC7A11 promotes EMT and metastasis in invasive pituitary neuroendocrine tumors by activating the PI3K/AKT signaling pathway.","authors":"Shikai Gui, Wanli Yu, Jiabao Xie, Lunshan Peng, Yuanyuan Xiong, Zhen Song, Haitao Luo, Juexian Xiao, Shengtao Yuan, Zujue Cheng","doi":"10.1530/EC-24-0097","DOIUrl":"10.1530/EC-24-0097","url":null,"abstract":"<p><p>Invasive pituitary neuroendocrine tumors (PitNETs) are the most prevalent types of intracranial and neuroendocrine tumors. Their aggressive growth and difficulty in complete resection result in a high recurrence rate. Cystine transporter solute carrier family 7 member 11 (SLC7A11) is overexpressed in various cancers, which contributes to tumor growth, progression, and metastasis by promoting cystine uptake and glutathione biosynthesis. We identified SLC7A11 as an invasive biomarker based on three Gene Expression Omnibus cohorts. This study aimed to investigate the role of SLC7A11 in invasive PitNETs. Cell proliferation was assessed using CCK-8 and colony formation assays, while cell apoptosis was estimated with flow cytometry. Wound healing assays and transwell assays were utilized to evaluate migration and invasion ability. Our findings demonstrated that SLC7A11 was markedly upregulated in invasive PitNETs, and was associated with the invasiveness of PitNETs. Knockdown of SLC7A11 could largely suppress tumor cell proliferation, migration, and invasion, while inducing apoptosis. Furthermore, SLC7A11 depletion was implicated in regulating epithelial-mesenchymal transition and inactivating the PI3K/AKT signaling pathway. These insights suggest SLC7A11 as a potential therapeutic target for invasive PitNETs.</p>","PeriodicalId":11634,"journal":{"name":"Endocrine Connections","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Endocrine Connections
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1